Trial Profile
Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete Responders
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2022
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary)
- Indications B-cell lymphoma; Lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 19 May 2021 Planned number of patients changed from 120 to 60.
- 05 May 2020 Planned End Date changed from 18 Apr 2021 to 1 Jan 2025.
- 05 May 2020 Planned primary completion date changed from 18 Apr 2021 to 1 Jan 2024.